Anti-B cell antibody therapies for inflammatory rheumatic diseases

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 263-278

  Faurschou, Mikkel ^a   Jayne, David R W ^b  

^a Rigshospitalet   (Denmark)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

B cell targeted therapy; Myositis; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus; Vasculitis

Indexed keywords

ATACICEPT; B LYMPHOCYTE ANTIBODY; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; DAS28; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MICROSCOPIC POLYANGIITIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DERMATOMYOSITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 2; SJOGREN'S SYNDROME;

EID: 84900502132     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-070912-133235     Document Type: Review

References (73)

1. Miller AV, Ranatunga SK. 2012. Immunotherapies in rheumatologic disorders. Med. Clin. North Am. 96(3):475-96
2. McInnes IB, Schett G. 2011. The pathogenesis of rheumatoid arthritis. N. Engl. J.Med. 365(23):2205-19
3. Helmick CG, Felson DT, Lawrence RC, et al. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58(1):15-25
4. Gabriel SE. 2008. Why do people with rheumatoid arthritis still die prematurely? Ann. Rheum. Dis. 67(Suppl. 3):iii30-34
5. Edwards JC, Cambridge G. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40(2):205-11
6. Edwards JC, Szczepanski L, Szechinski J, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25):2572-81
7. Cohen SB, Emery P, Greenwald MW, et al. 2006. Rituximab for rheumatoid arthritis refractory to anti- tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9):2793- 806 (Pubitemid 44497758)
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despitemethotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5):1390-400
9. Keystone E, Emery P, Peterfy CG, et al. 2009. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. 68(2):216-21
10. Cohen SB, Keystone E, Genovese MC, et al. 2010. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann. Rheum. Dis. 69(6):1158-61
11. Tak PP, Rigby WF, Rubbert-Roth A, et al. 2011. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70(1):39-46
12. Tak PP, Rigby W, Rubbert-Roth A, et al. 2012. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann. Rheum. Dis. 71(3):351-57
13. Mease PJ, Cohen S, Gaylis NB, et al. 2010. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J. Rheumatol. 37(5):917-27
14. Rubbert-Roth A, Tak PP, Zerbini C, et al. 2010. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49(9):1683-93
15. Emery P, Deodhar A, Rigby WF, et al. 2010. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate. Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE). Ann. Rheum. Dis. 69(9):1629-35
16. Buch MH, Smolen JS, Betteridge N, et al. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(6):909-20
17. Benucci M, Saviola G, Manfredi M, et al. 2013. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics 7:69-75
18. Raterman HG, Levels H, Voskuyl AE, et al. 2013. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis. 72(4):560-65
19. OstergaardM, Baslund B, Rigby W, et al. 2010. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 62(8):2227-38
20. Taylor PC, Quattrocchi E, Mallett S, et al. 2011. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70(12):2119-25
21. GenoveseMC, Kaine JL, Lowenstein MB, et al. 2008. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patientswith rheumatoid arthritis: a phase I/II randomized, blinded, placebocontrolled, dose-ranging study. Arthritis Rheum. 58(9):2652-61
22. Rigby W, Tony HP, Oelke K, et al. 2012. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, doubleblind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64(2):350-59
23. Tak PP, Mease PJ, Genovese MC, et al. 2012. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64(2):360-70
24. Stohl W, Gomez-Reino J, Olech E, et al. 2012. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann. Rheum. Dis. 71(8):1289-96
25. HarigaiM, Tanaka Y, Maisawa S. 2012. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebocontrolled double-blind parallel-group study. J. Rheumatol. 39(3):486-95
26. McKay J, Chwalinska-Sadowska H, Boling E, et al. 2005. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces signs and symptoms of rheumatoid arthritis in a heterogenous subject population. Arthritis Rheum. 52(9, Suppl.):710-11
27. Tak PP, Thurlings RM, Rossier C, et al. 2008. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58(1):61-72
28. Genovese MC, Kinnman N, de La Bourdonnaye G, et al. 2011. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63(7):1793-803
29. van Vollenhoven RF, Kinnman N, Vincent E, et al. 2011. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63(7):1782-92
30. Bernatsky S, Boivin JF, Joseph L, et al. 2006. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54(8):2550-57 (Pubitemid 44205016)
31. Manzi S, Meilahn EN, Rairie JE, et al. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145(5):408-15
32. Bjornadal L, Yin L, Granath F, et al. 2004. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J. Rheumatol. 31(4):713-19 (Pubitemid 38451257)
33. FaurschouM, Mellemkjaer L, Starklint H, et al. 2011. High risk of ischemic heart disease in patients with lupus nephritis. J. Rheumatol. 38(11):2400-5
34. Cervera R, Khamashta MA, Font J, et al. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine (Baltimore) 82(5):299-308 (Pubitemid 37229465)
35. Jacobsen S, Petersen J, Ullman S, et al. 1998. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I.Disease manifestations and analyses of clinical subsets. Clin. Rheumatol. 17(6):468- 77
36. Houssiau FA, Ginzler EM. 2008. Current treatment of lupus nephritis. Lupus 17(5):426-30 (Pubitemid 351798721)
37. Furtado J, Isenberg DA. 2013. B cell elimination in systemic lupus erythematosus. Clin. Immunol. 146(2):90-103
38. Merrill JT, Neuwelt CM, Wallace DJ, et al. 2010. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1):222-33
39. Rovin BH, Furie R, Latinis K, et al. 2012. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64(4):1215-26
40. Mysler EF, Spindler AJ, Guzman R, et al. 2010. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, doubleblind phase III BELONG study. Arthritis Rheum. 62(10, Suppl.):606-7
41. Petri M, Hobbs K, Gordon C, et al. 2008. Randomized controlled trials (RCTs) of epratuzumab (anti- CD22 mab targeting B-cells) reveal clinically meaningful improvements in patients (Pts) with moderate/severe SLE flares. Ann. Rheum. Dis. 67(Suppl. II):53
42. Wallace D, Hobbs K, Houssiau F, et al. 2008. Randomized controlled trials of epratuzumab (anti-CD22 mab targeting B-cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients. Ann. Rheum. Dis. 67(Suppl. II):212
43. Wallace DJ, Kalunian K, Petri MA, et al. 2013. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. Epub ahead of print.
44. FurieR, Petri M, Zamani O, et al. 2011.Aphase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patientswith systemic lupus erythematosus. Arthritis Rheum. 63(12):3918-30
45. Navarra SV, Guzman RM, Gallacher AE, et al. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721- 31
46. Dooley MA, Houssiau F, Aranow C, et al. 2013. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22(1):63-72
47. Ginzler EM, Wax S, Rajeswaran A, et al. 2012. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14(1):R33
48. Jennette JC, Falk RJ, Bacon PA, et al. 2013. 2012 revised International Chapel Hill ConsensusConference Nomenclature of Vasculitides. Arthritis Rheum. 65(1):1-11
49. Hoffman GS, Kerr GS, Leavitt RY, et al. 1992. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116(6):488-98
50. Westman KW, Bygren PG, Olsson H, et al. 1998. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Nephrol. 9(5):842-52
51. Knight A, Askling J, Ekbom A. 2002. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int. J. Cancer 100(1):82-85 (Pubitemid 34602069)
52. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. 2008. Malignancies inWegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35(1):100-5
53. Jayne D, Rasmussen N, Andrassy K, et al. 2003. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349(1):36-44
54. De Groot K, Rasmussen N, Bacon PA, et al. 2005. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52(8):2461-69 (Pubitemid 41117433)
55. De Groot K, Harper L, Jayne DR, et al. 2009. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150(10):670-80
56. Stone JH, Merkel PA, Spiera R, et al. 2010. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363(3):221-32
57. Jones RB, Tervaert JW, Hauser T, et al. 2010. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363(3):211-20
58. Faurschou M, Westman K, Rasmussen N, et al. 2012. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64(10):3472-77
59. Harper L, Morgan MD, Walsh M, et al. 2012. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71(6):955-60
60. Jones RB, Ferraro AJ, Chaudhry AN, et al. 2009. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60(7):2156-68
61. Guillevin L, Pagnoux C, Karras A, et al. 2013. Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis. A prospective study in 117 patients. Presse Med. 424(Pt. 2):679
62. Rider LG, Miller FW. 2011. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183-90
63. Oddis CV, Reed AM, Aggarwal R, et al. 2013. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65(2):314-24
64. Fox RI. 2005. Sjogren's syndrome. Lancet 366(9482):321-31
65. Dass S, Bowman SJ, Vital EM, et al. 2008. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67(11):1541-44
66. Meijer JM, Meiners PM, Vissink A, et al. 2010. Effectiveness of rituximab treatment in primary Sj ogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62(4):960-68
67. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. 2012. Tolerance and efficacy of rituximab in primary Sjogren syndrome: final results of a randomized controlled trial. Arthritis Rheum. 64(10, Suppl.):1079
68. van Vollenhoven RF, Emery P, Bingham CO, et al. 2010. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37(3):558-67
69. Gottenberg JE, Ravaud P, Bardin T, et al. 2010. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 62(9):2625-32
70. Terrier B, Amoura Z, Ravaud P, et al. 2010. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62(8):2458-66
71. Clifford DB, Ances B, Costello C, et al. 2011. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68(9):1156-64
72. Molloy ES, Calabrese LH. 2009. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60(12):3761- 65
73. Merrill JT, Ginzler EM, Wallace DJ, et al. 2012. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 64(10):3364-73